NCT05682703

Brief Summary

The transformation process of nasopharyngeal carcinoma is complex, so it is particularly important to explore the relationship between various disease states on its clinical pathway. Therefore, we carried out this study to explore the changes of plasma and urine metabolites at different stages during the occurrence and development of nasopharyngeal carcinoma.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 23, 2022

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

January 4, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 12, 2023

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 20, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2025

Completed
Last Updated

January 12, 2023

Status Verified

December 1, 2022

Enrollment Period

2.9 years

First QC Date

January 4, 2023

Last Update Submit

January 4, 2023

Conditions

Nasopharyngeal CarcinomaEBV Infection

Outcome Measures

Primary Outcomes (1)

  • Achieve the expected number of enrolled cases

    Achieve the expected number of enrolled cases

    3 years

Study Arms (3)

EBV virus infector

QPCR/EBV antibody, diagnosed as EBV infection patient

Diagnostic Test: Proteomics technology and liquid biopsy

nasopharyngeal carcinoma patients

Patients diagnosed as nasopharyngeal carcinoma by pathological diagnosis (2018 WHO standard)

Diagnostic Test: Proteomics technology and liquid biopsy

Healthy people

healthy people with no history of nasopharynx related diseases or other known diseases that may affect blood lipid/protein metabolism

Diagnostic Test: Proteomics technology and liquid biopsy

Interventions

Proteomics technology and liquid biopsyDIAGNOSTIC_TEST

using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites by collecting residual blood and urine from routine diagnosis and treatment or physical examination

EBV virus infectorHealthy peoplenasopharyngeal carcinoma patients

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Subjects who met the diagnosis and criteria and were admitted to Nanfang Hospital of Southern Medical University.

You may qualify if:

  • EBV virus infector: QPCR/EBV antibody, diagnosed as EBV infection patient with previous infection;
  • Nasopharyngeal carcinoma patients:Patients diagnosed as nasopharyngeal carcinoma by pathological diagnosis (2018 WHO standard);
  • Healthy people: Healthy people who have no history of nasopharynx related diseases or other known diseases that may affect blood lipid/protein metabolism and have been hospitalized in the Physical Examination Center of Southern Hospital.

You may not qualify if:

  • People who have a history of non research related liver diseases or other diseases known to affect blood metabolism (except for controlled type II diabetes);
  • Have a history of other malignant tumors, except for fully treated basal cell carcinoma or squamous cell carcinoma and cervical carcinoma in situ;
  • Diseases requiring long-term use of immunosuppressive drugs (including steroids), including but not limited to congenital or acquired immunodeficiency diseases or active central nervous system metastatic cancer, active infection or uncontrolled heart disease;
  • Suffer from other uncontrolled serious diseases at the same time, such as unstable heart disease requiring treatment, diabetes with unsatisfactory control (fasting blood glucose\>1.5 Ă— Upper limit of normal value), mental illness and severe allergic history.
  • BMI is less than 18 or more than 25. -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Southern medical university

Guangzhou, Guangdong, 510515, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Plasma and Urine

MeSH Terms

Conditions

Nasopharyngeal CarcinomaEpstein-Barr Virus Infections

Interventions

Liquid Biopsy

Condition Hierarchy (Ancestors)

CarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsNasopharyngeal NeoplasmsPharyngeal NeoplasmsOtorhinolaryngologic NeoplasmsHead and Neck NeoplasmsNeoplasms by SiteNasopharyngeal DiseasesPharyngeal DiseasesStomatognathic DiseasesOtorhinolaryngologic DiseasesHerpesviridae InfectionsDNA Virus InfectionsVirus DiseasesInfectionsTumor Virus Infections

Intervention Hierarchy (Ancestors)

BiopsyCytodiagnosisCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisSpecimen HandlingInvestigative Techniques

Study Officials

  • jian guan, MD

    Nanfang Hospital, Southern Medical University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

jian guan, MD

CONTACT

136 3210 2247guanjian5461@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 4, 2023

First Posted

January 12, 2023

Study Start

December 23, 2022

Primary Completion

November 20, 2025

Study Completion

December 20, 2025

Last Updated

January 12, 2023

Record last verified: 2022-12

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)